home

What's in a name? Plenty, if you're in the Merck vs. Merck trademark fight

EVENTSfiercepharma2016-04-19 13:24 Read   105

The Merck vs. Merck trademark spat just heated up with Germany-based Merck KGaA striking back at U.S.-based Merck & Co. with its own infringement allegations.

First Presentation of Two-Year Overall Survival Data for Opdivo® (nivolumab) in Combination with Yervoy® (ipilimumab) Showed Superior Efficacy Versus Yervoy Alone in Advanced Melanoma

TrendBristol-Myers Squibb Company2016-04-19 11:36 Read   67

Bristol-Myers Squibb Company (NYSE:BMY) announced today first time presentation of overall survival data from CheckMate -069, a Phase 2 trial and the first randomized study to evaluate the Opdivo and Yervoy combination regimen in patients with previously untreated advanced melanoma.

Nationwide Reveals the 10 Most Common Medical Conditions for Dogs and Cats

TrendNationwide2016-04-19 11:05 Read   83

Nation's Largest Pet Insurer Unveils Top Pet Ailments that Prompt Veterinary Visits

CHAI Announces Partnership with Governments in Six Low- and Middle-Income Countries to Initiate and Expand Hepatitis C Treatment Programs

Frontierbusinesswire2016-04-19 10:56 Read   77

Ministries of Health in Ethiopia, Indonesia, Myanmar, Nigeria, Rwanda, and Vietnam are accelerating access to hepatitis C (HCV) testing and treatment with technical assistance from the Quick-Start program, which aims to cure 25,000 people of HCV in the next two years.

NICE backs first Duchenne muscular dystrophy drug

Frontierpmlive2016-04-19 10:48 Read   65

NICE has reversed an earlier decision to reject PTC Therapeutics' Duchenne muscular dystrophy (DMD) drug Translarna, but has warned access to the pricey drug will have to be carefully managed

Health Tip: Easing Eye Allergies

HealthDRUGS2016-04-19 10:43 Read   83

When your eyes turn red, water and itch, it can make you miserable.

Transition Therapeutics Provides Update on Type 2 Diabetes Drug Candidate TT401

TrendTransition Therapeutics2016-04-19 10:38 Read   63

Transition Therapeutics Inc. today announced that it has received notification that Eli Lilly and Co.(“Lilly”) will not elect to advance diabetes drug candidate, TT401 into Phase 3 development.

AstraZeneca mulls £7bn move for prostate cancer drug company Medivation

Frontiertelegraph2016-04-19 10:31 Read   114

AstraZeneca is mulling a £7bn offer for the US drug company Medivation after it rejected a bid from a French rival.

AbbVie Presents New Phase 2 Data for Investigational, Once-Daily, Ribavirin-Free, Pan-Genotypic Regimen of ABT-493 and ABT-530 for Hepatitis C Genotypes 1-6

Trendabbvie2016-04-19 10:26 Read   72

AbbVie today announced that with eight weeks of treatment, 97-98 percent of genotype 1-3 (GT1-3) chronic hepatitis C virus (HCV) infected patients without cirrhosis treated with AbbVie's investigational, once-daily, ribavirin (RBV)-free, pan-genotypic regimen of ABT-493 and ABT-530 achieved sustained virologic response at 12 weeks post-treatment (SVR12).

Loxo Oncology TRK Inhibitor LOXO-101 Shows Durable Anti-Tumor Activity Across TRK Fusion Cancers in AACR Phase 1 Update

Trendloxooncology2016-04-19 10:14 Read   62

Loxo Oncology, Inc. (Nasdaq:LOXO), today announced new results from its Phase 1 open-label, dose-escalation trial of LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK).

Stem cell biotech BioCardia drops $50M IPO

Frontierfiercebiotech2016-04-19 10:00 Read   78

A new week, another ditched IPO as BioCardia fails to find enough interest in its regenerative heart failure candidate in a tough financial market.

New Digital Company Attacks Hard-To-Kill Cancer With Software

Frontiergereports2016-04-19 09:55 Read   77

No one illustrates the promise of cell therapy better than a little girl named Emily Whitehead. She was just 5 years old when she got sick with a common type of childhood cancer called acute lymphoblastic leukemia. Roughly 98 percent of children go into remission within weeks of treatment, but Emily relapsed repeatedly despite several rounds of chemotherapy.